The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging

Haejin In, Ethan Ravetch, Marisa Langdon-Embry, Bryan Palis, Jaffer A. Ajani, Wayne L. Hofstetter, David P. Kelsen, Takeshi Sano

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: New stage grouping classifications for clinical (cStage) and post-neoadjuvant treatment (ypStage) stage for gastric adenocarcinoma have been proposed for the eighth edition of the AJCC manual. This article summarizes the analysis for these stages. Methods: Gastric adenocarcinoma patients diagnosed in 2004–2009 were identified from the National Cancer Database (NCDB). The cStage cohort included both surgical and nonsurgical cases, and the ypStage cohort included only patients who had chemotherapy or radiation therapy before surgery. Survival differences between the stage groups were determined by the log-rank test and prognostic accuracy was assessed by concordance index. Analysis was performed using SAS 9.4 (SAS, Cary, NC, USA). Results: Five strata for cStage and four strata for ypStage were developed. The 5-year survival rates for cStages were 56.77%, 47.39%, 33.1%, 25.9%, and 5.0% for stages I, IIa, IIb, III, and IV, respectively, and the rates for ypStage were 74.2%, 46.3%, 19.2%, and 11.6% for stages I, II, III, and IV, respectively. The log-rank test showed that survival differences were well stratified and stage groupings were ordered and distinct (p < 0.0001). The proposed cStage and ypStage classification was sensitive and specific and had high prognostic accuracy (cStage: c index = 0.81, 95% CI, 0.79–0.83; ypStage: c index = 0.80, 95% CI, 0.73–0.87). Conclusion: The proposed eighth edition establishes two new staging schemata that provide essential prognostic data for patients before treatment and for patients who have undergone surgery following neoadjuvant therapy. These additions are a significant advance to the AJCC staging manual and will provide critical guidance to clinicians in making informed decisions throughout the treatment course.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalGastric Cancer
DOIs
StateAccepted/In press - Sep 25 2017

Fingerprint

Neoadjuvant Therapy
Neoplasm Staging
Stomach
Adenocarcinoma
Survival
Neoplasms
Decision Making
Radiotherapy
Survival Rate
Databases
Drug Therapy
Therapeutics

Keywords

  • AJCC
  • Clinical stage (cStage)
  • Gastric adenocarcinoma
  • Post-neoadjuvant treatment stage (ypStage)
  • Staging

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. / In, Haejin; Ravetch, Ethan; Langdon-Embry, Marisa; Palis, Bryan; A. Ajani, Jaffer; Hofstetter, Wayne L.; Kelsen, David P.; Sano, Takeshi.

In: Gastric Cancer, 25.09.2017, p. 1-9.

Research output: Contribution to journalArticle

In, Haejin ; Ravetch, Ethan ; Langdon-Embry, Marisa ; Palis, Bryan ; A. Ajani, Jaffer ; Hofstetter, Wayne L. ; Kelsen, David P. ; Sano, Takeshi. / The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. In: Gastric Cancer. 2017 ; pp. 1-9.
@article{596970be371a4560b1722fa3aa99e878,
title = "The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging",
abstract = "Purpose: New stage grouping classifications for clinical (cStage) and post-neoadjuvant treatment (ypStage) stage for gastric adenocarcinoma have been proposed for the eighth edition of the AJCC manual. This article summarizes the analysis for these stages. Methods: Gastric adenocarcinoma patients diagnosed in 2004–2009 were identified from the National Cancer Database (NCDB). The cStage cohort included both surgical and nonsurgical cases, and the ypStage cohort included only patients who had chemotherapy or radiation therapy before surgery. Survival differences between the stage groups were determined by the log-rank test and prognostic accuracy was assessed by concordance index. Analysis was performed using SAS 9.4 (SAS, Cary, NC, USA). Results: Five strata for cStage and four strata for ypStage were developed. The 5-year survival rates for cStages were 56.77{\%}, 47.39{\%}, 33.1{\%}, 25.9{\%}, and 5.0{\%} for stages I, IIa, IIb, III, and IV, respectively, and the rates for ypStage were 74.2{\%}, 46.3{\%}, 19.2{\%}, and 11.6{\%} for stages I, II, III, and IV, respectively. The log-rank test showed that survival differences were well stratified and stage groupings were ordered and distinct (p < 0.0001). The proposed cStage and ypStage classification was sensitive and specific and had high prognostic accuracy (cStage: c index = 0.81, 95{\%} CI, 0.79–0.83; ypStage: c index = 0.80, 95{\%} CI, 0.73–0.87). Conclusion: The proposed eighth edition establishes two new staging schemata that provide essential prognostic data for patients before treatment and for patients who have undergone surgery following neoadjuvant therapy. These additions are a significant advance to the AJCC staging manual and will provide critical guidance to clinicians in making informed decisions throughout the treatment course.",
keywords = "AJCC, Clinical stage (cStage), Gastric adenocarcinoma, Post-neoadjuvant treatment stage (ypStage), Staging",
author = "Haejin In and Ethan Ravetch and Marisa Langdon-Embry and Bryan Palis and {A. Ajani}, Jaffer and Hofstetter, {Wayne L.} and Kelsen, {David P.} and Takeshi Sano",
year = "2017",
month = "9",
day = "25",
doi = "10.1007/s10120-017-0765-y",
language = "English (US)",
pages = "1--9",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",

}

TY - JOUR

T1 - The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging

AU - In, Haejin

AU - Ravetch, Ethan

AU - Langdon-Embry, Marisa

AU - Palis, Bryan

AU - A. Ajani, Jaffer

AU - Hofstetter, Wayne L.

AU - Kelsen, David P.

AU - Sano, Takeshi

PY - 2017/9/25

Y1 - 2017/9/25

N2 - Purpose: New stage grouping classifications for clinical (cStage) and post-neoadjuvant treatment (ypStage) stage for gastric adenocarcinoma have been proposed for the eighth edition of the AJCC manual. This article summarizes the analysis for these stages. Methods: Gastric adenocarcinoma patients diagnosed in 2004–2009 were identified from the National Cancer Database (NCDB). The cStage cohort included both surgical and nonsurgical cases, and the ypStage cohort included only patients who had chemotherapy or radiation therapy before surgery. Survival differences between the stage groups were determined by the log-rank test and prognostic accuracy was assessed by concordance index. Analysis was performed using SAS 9.4 (SAS, Cary, NC, USA). Results: Five strata for cStage and four strata for ypStage were developed. The 5-year survival rates for cStages were 56.77%, 47.39%, 33.1%, 25.9%, and 5.0% for stages I, IIa, IIb, III, and IV, respectively, and the rates for ypStage were 74.2%, 46.3%, 19.2%, and 11.6% for stages I, II, III, and IV, respectively. The log-rank test showed that survival differences were well stratified and stage groupings were ordered and distinct (p < 0.0001). The proposed cStage and ypStage classification was sensitive and specific and had high prognostic accuracy (cStage: c index = 0.81, 95% CI, 0.79–0.83; ypStage: c index = 0.80, 95% CI, 0.73–0.87). Conclusion: The proposed eighth edition establishes two new staging schemata that provide essential prognostic data for patients before treatment and for patients who have undergone surgery following neoadjuvant therapy. These additions are a significant advance to the AJCC staging manual and will provide critical guidance to clinicians in making informed decisions throughout the treatment course.

AB - Purpose: New stage grouping classifications for clinical (cStage) and post-neoadjuvant treatment (ypStage) stage for gastric adenocarcinoma have been proposed for the eighth edition of the AJCC manual. This article summarizes the analysis for these stages. Methods: Gastric adenocarcinoma patients diagnosed in 2004–2009 were identified from the National Cancer Database (NCDB). The cStage cohort included both surgical and nonsurgical cases, and the ypStage cohort included only patients who had chemotherapy or radiation therapy before surgery. Survival differences between the stage groups were determined by the log-rank test and prognostic accuracy was assessed by concordance index. Analysis was performed using SAS 9.4 (SAS, Cary, NC, USA). Results: Five strata for cStage and four strata for ypStage were developed. The 5-year survival rates for cStages were 56.77%, 47.39%, 33.1%, 25.9%, and 5.0% for stages I, IIa, IIb, III, and IV, respectively, and the rates for ypStage were 74.2%, 46.3%, 19.2%, and 11.6% for stages I, II, III, and IV, respectively. The log-rank test showed that survival differences were well stratified and stage groupings were ordered and distinct (p < 0.0001). The proposed cStage and ypStage classification was sensitive and specific and had high prognostic accuracy (cStage: c index = 0.81, 95% CI, 0.79–0.83; ypStage: c index = 0.80, 95% CI, 0.73–0.87). Conclusion: The proposed eighth edition establishes two new staging schemata that provide essential prognostic data for patients before treatment and for patients who have undergone surgery following neoadjuvant therapy. These additions are a significant advance to the AJCC staging manual and will provide critical guidance to clinicians in making informed decisions throughout the treatment course.

KW - AJCC

KW - Clinical stage (cStage)

KW - Gastric adenocarcinoma

KW - Post-neoadjuvant treatment stage (ypStage)

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=85029815377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029815377&partnerID=8YFLogxK

U2 - 10.1007/s10120-017-0765-y

DO - 10.1007/s10120-017-0765-y

M3 - Article

SP - 1

EP - 9

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

ER -